Sammanfattning
BCR::ABL1-independent pathways contribute to primary resistance to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) and play a role in leukemic stem cell persistence. Here, we perform ex vivo drug screening of CML CD34+ leukemic stem/progenitor cells using 100 single drugs and TKI-drug combinations and identify sensitivities to Wee1, MDM2, and BCL2 inhibitors. These agents effectively inhibit primitive CD34+CD38− CML cells and demonstrate potent synergies when combined with TKIs. Flow-cytometry-based drug screening identifies mepacrine to induce differentiation of CD34+CD38− cells. We employ genome-wide CRISPR-Cas9 screening for six drugs, and mediator complex, apoptosis, and erythroid-lineage-related genes are identified as key resistance hits for TKIs, whereas the Wee1 inhibitor AZD1775 and mepacrine exhibit distinct resistance profiles. KCTD5, a consistent TKI-resistance-conferring gene, is found to mediate TKI-induced BCR::ABL1 ubiquitination. In summary, we delineate potential mechanisms for primary TKI resistance and non-BCR::ABL1-targeting drugs, offering insights for optimizing CML treatment.
Originalspråk | engelska |
---|---|
Artikelnummer | 101521 |
Tidskrift | Cell Reports Medicine |
Volym | 5 |
Nummer | 5 |
Antal sidor | 23 |
ISSN | 2666-3791 |
DOI | |
Status | Publicerad - 21 maj 2024 |
MoE-publikationstyp | A1 Tidskriftsartikel-refererad |
Bibliografisk information
Publisher Copyright:© 2024 The Authors
Vetenskapsgrenar
- 3111 Biomedicinska vetenskaper
- 1182 Biokemi, cell- och molekylärbiologi